Floatz logo

Sotagliflozin

Anthracycline-induced Cardiotoxicity

Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Anthracycline-induced Cardiotoxicity cohort.

Asset / SponsorPhaseRating
Rosuvastatin
Shiraz University of Medical Sciences
Phase 4BB
Dapagliflozin
University Medical Centre Ljubljana
Phase 2CCC
SFX-01 (SULFORAPHANE STABILIZED WITH .ALPHA. CYCLODEXTRIN)
Texas Tech University Health Sciences Center
Phase 1/2CCC
Allo-Mscs
The University of Texas Health Science Center, Houston
Phase 1CC

Same molecule, other indications

Sotagliflozin is also rated in:

cancerDormant
CCC
Indicative ·
53 / 100
View asset →
heart disorderDormant
CCC
Indicative ·
53 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →